I liked the comment by Dr. Sternberg that, "Many patients got out of bed, and started walking again".
<<In your presentation, you mentioned cabozantinib. Are there any recent data on that drug?
Cabozantinib is a dual inhibitor of the VEGF receptor and MET. A randomized discontinuation phase II trial design was used to evaluate cabozantinib. The randomization of stable patients to cabozantinib or placebo was stopped early because of the dramatic results observed. At 12 weeks, cabozantinib achieved a 74% regression of soft-tissue lesions, 19% complete remission (CR) of bone metastases, and 56% partial remission (PR) of bone metastasis. Many patients got out of bed and started walking again. This drug will be evaluated in a larger study and the endpoint will be pain improvement, and a second study will evaluate OS.>>
Cabozantinib has been submitted to FDA approval for thyroid cancer. If approved, can it be prescribed on the other forms of cancer which have shown such promise in their own trials, such as prostate for bone metastasis? Many of those phase 3 trials will be completed mid 2014. If current test results continue, cabo will be in very high demand worldwide.
It's too bad Dr Sternberg's comment, "Many patients got out of bed, and started walking again"., will go unnoticed by the majority of the public. Possibly the medical and investment community as well? It was only reported in an obscure med. periodical. It would be nice to have that reported by AP and so forth. People connected with Cabo. often mention it gives pain relief and people reduce or stop narcotics. It would be nice if they also included her statement. After all pain relief is what Exel is going for first. I think Invsetor Relations and future company presentions should stress that fact. Good Luck!
Good find !! I particularly like these interviews that show the support from clinicians. Should CABO approval somehow come to a "push", it may just be the clinical opinion that sways the balance beam. GLTA